Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies

• المؤلفون الرئيسيون: Nicholas R. Liguori (مؤلف), Young Lee (مؤلف), William Borges (مؤلف), Lanlan Zhou (مؤلف), Christopher Azzoli (مؤلف), Wafik S. El-Deiry (مؤلف)
• التنسيق: كتاب
• منشور في: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Lung cancer is the second most common cancer in the United States, and small cell lung cancer (SCLC) accounts for about 15% of all lung cancers. In SCLC, more than other malignancies, the standard of care is based on clinical demonstration of efficacy, and less on a mechanistic understanding of why...